The funding awarded by CQDM to innovative research projects is possible with the financial support of its public and private partners: the Business-Led Networks of Centres of Excellence (BL-NCE), the Ministère du Développement Économique, de l’Innovation et de l’Exportation (MDEIE), the Fonds de la Recherche du Québec - Santé (FRQS), as well as 6 large pharmaceutical companies AstraZeneca, Merck, Pfizer, Boehringer Ingelheim, Eli Lilly and GlaxoSmithKline. In addition, by being closely involved in the activities of CQDM, these partners bring a vast expertise and support necessary to the expansion of CQDM’s mission. Through their commitments, they contribute to the advancement of biopharmaceutical research for the development of safer and more effective new drugs.
AstraZeneca is one of the world's leading pharmaceutical companies with health care sales of US $31.6 billion and an extensive product portfolio spanning six major therapeutic areas: cardiovascular, gastrointestinal, infection, neuroscience, oncology and respiratory. AstraZeneca's brands include: Crestor®, Symbicort®, Nexium®, Atacand®, Seroquel® and Arimidex®. For the third consecutive year, AstraZeneca has been recognized by R&D Directions magazine as having the most innovative early pipeline. With 17 principal research centers in 8 countries around the world, AstraZeneca invested more than $5 billion in drug discovery and development in 2008. AstraZeneca's Canadian headquarters are located in Mississauga, Ontario, and the company's state-of-the-art analgesia drug discovery centre is in Montreal, Québec.
For more information, visit: www.astrazeneca.ca
Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products to the people who need them. Merck. Be Well.
For more information about Merck in Canada, visit: www.merck.ca.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world's leading pharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals. Pfizer Inc. invests more than US $7 billion annually in R&D to discover and develop innovative life-saving and life-enhancing medicines in a wide range of therapeutic areas, including arthritis, cardiovascular disease, endocrinology, HIV/AIDS, infectious disease, neurological disease, oncology, ophthalmology and smoking cessation. Pfizer Canada is one of the top investors in Canadian R&D, investing more than $1 billion since 2000. Headquartered in Kirkland, Québec, Pfizer Canada and its cross-Canada team of 1,200 employees are working together for a healthier world. Pfizer Canada’s commitment to helping Canadians live happier, healthier and longer lives extends beyond medication.
To learn more about Pfizer Canada’s more than medication philosophy and programs, visit: www.morethanmedication.ca.
Business-Led Networks of Centres of Excellence
This program is administered by the Networks of Centres of Excellence (NCE) Secretariat. Launched in 1989, the NCE is an initiative of the three federal granting agencies—the Natural Sciences and Engineering Research Council of Canada (NSERC), the Social Sciences and Humanities Research Council of Canada (SSHRC) and the Canadian Institutes for Health Research (CIHR)—in partnership with Industry Canada.
The Business-Led Networks of Centres of Excellence program supports large-scale, collaborative research networks. BL-Networks aim at enhancing private sector innovation, delivering benefits to Canadians and encouraging an Entrepreneurial Advantage.”
For more information, visit: www.nce.gc.ca
For more information, visit: http://www.mesrst.gouv.qc.ca/ministere/mission/
Funding Partners Explore
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, independent family-owned Boehringer Ingelheim operates globally with more than 42,000 employees in 145 affiliates that include a network of research and development facilities and production sites in 13 countries. Since 1885, Boehringer Ingelheim has been committed to researching, developing, manufacturing and marketing innovative pharmaceuticals that represent major therapeutic advances and improve human and animal health. Our drug discovery focuses on six major therapeutic areas: respiratory diseases, cardiometabolic diseases, oncology, neurological diseases, immunology and infectious diseases. In 2010, Boehringer Ingelheim posted net sales of 12.6 billion euro while investing almost 24% of net sales on research and development in prescription medicines, its largest business segment.
Boehringer Ingelheim’s Canadian operations are home to 700 employees working for health across the country with headquarters in Burlington, Ontario and a well-established state-of-the-art research centre in Laval, Quebec where more than 140 scientists are dedicated to infectious diseases research.
To learn more about Boehringer Ingelheim and its vision of Value through Innovation, visit: www.boehringer-ingelheim.com.
As a leading innovation-driven pharmaceutical corporation, Lilly is developing a growing portfolio of best-in-class and first-in-class pharmaceutical products by applying the latest research from our own worldwide laboratories, by collaborating with eminent scientific organizations, by making use of the most up-to-date technological tools, and by providing exceptional service to our customers.
Lilly is committed to providing answers that matter in medicine, life sciences and health care. Through internal programs and external initiatives, we’re seeking answers for some of the world’s most urgent medical needs.
Founded by Colonel Eli Lilly in 1876, and now 135 years later, generations of employees still rely on the long-established core values - excellence, integrity and respect for people – that guide them in all that they do.
Additional information about Eli Lilly Canada can be found at www.lilly.ca
GlaxoSmithKline (GSK) is a leading research-based pharmaceutical company with a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better, and live longer. This mission gives GSK the purpose to develop innovative medicines, vaccines and healthcare solutions that help millions of people. GSK is consistently recognized as one of the 50 best employers in Canada and is a top 15 investor in Canadian research and development, contributing more than $144 million in 2009 alone. With a proud tradition of charitable and community support, GSK is designated a Caring Company by Imagine Canada.
Discover more at www.gsk.ca.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2011, the company invested close to $100 million in research and development in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. It was named for the seventh time as one of the “50 Best Employers in Canada” for 2011.
For further information, please consult www.novartis.ca.